公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2019 | Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation | CHIH-HSIN YANG ; Gadgeel S.M; Sequist L.V; Wu C.-L; Papadimitrakopoulou V.A; Su W.-C; Fiore J; Saraf S; Raftopoulos H; Patnaik A. | Journal of Thoracic Oncology | 130 | 104 |